Log in

NASDAQ:ONS - Oncobiologics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$0.72
MA: $2.15
$7.40
52-Week Range N/A
Volume781,008 shs
Average Volume69,024 shs
Market Capitalization$152.34 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.27
Oncobiologics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONS
CUSIPN/A
Phone609-619-3990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.81 million
Book Value($1.36) per share

Profitability

Net Income$-38,840,000.00
Net Margins-464.47%

Miscellaneous

EmployeesN/A
Market Cap$152.34 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ONS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.


Oncobiologics (NASDAQ:ONS) Frequently Asked Questions

What is Oncobiologics' stock symbol?

Oncobiologics trades on the NASDAQ under the ticker symbol "ONS."

Has Oncobiologics been receiving favorable news coverage?

Media headlines about ONS stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oncobiologics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Oncobiologics.

Who are some of Oncobiologics' key competitors?

What other stocks do shareholders of Oncobiologics own?

Who are Oncobiologics' key executives?

Oncobiologics' management team includes the folowing people:
  • Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Principal Accounting Officer, Company Sec.,Treasurer & Director (Age 52)
  • Dr. Pankaj Mohan, Founder & Director (Age 53)
  • Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 65)
  • Mr. Ralph H. Thurman, Exec. Chairman (Age 69)
  • Rick Gregory, Director of Marketing & Communications

When did Oncobiologics IPO?

(ONS) raised $35 million in an initial public offering on Friday, May 13th 2016. The company issued 5,800,000 shares at a price of $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

How big of a company is Oncobiologics?

Oncobiologics has a market capitalization of $0.00 and generates $3.81 million in revenue each year. View Additional Information About Oncobiologics.

What is Oncobiologics' official website?

The official website for Oncobiologics is http://www.oncobiologics.com/.

How can I contact Oncobiologics?

Oncobiologics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]


MarketBeat Community Rating for Oncobiologics (NASDAQ ONS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe ONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: Forex

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel